AU2003250831A1 - Use of hec1 antagonists in the treatment of proliferative disorders and cancer - Google Patents

Use of hec1 antagonists in the treatment of proliferative disorders and cancer

Info

Publication number
AU2003250831A1
AU2003250831A1 AU2003250831A AU2003250831A AU2003250831A1 AU 2003250831 A1 AU2003250831 A1 AU 2003250831A1 AU 2003250831 A AU2003250831 A AU 2003250831A AU 2003250831 A AU2003250831 A AU 2003250831A AU 2003250831 A1 AU2003250831 A1 AU 2003250831A1
Authority
AU
Australia
Prior art keywords
hec1
antagonists
cancer
treatment
proliferative disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250831A
Other languages
English (en)
Other versions
AU2003250831A8 (en
Inventor
Silvia Martin-Lluesma
Erich A. Nigg
Volker Stucke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU2003250831A8 publication Critical patent/AU2003250831A8/xx
Publication of AU2003250831A1 publication Critical patent/AU2003250831A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003250831A 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer Abandoned AU2003250831A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02013006.8 2002-06-12
EP02013006 2002-06-12
PCT/EP2003/006205 WO2003105891A2 (fr) 2002-06-12 2003-06-12 Utilisation d'antagonistes de hec1 dans le traitement de troubles proliferants et de cancers

Publications (2)

Publication Number Publication Date
AU2003250831A8 AU2003250831A8 (en) 2003-12-31
AU2003250831A1 true AU2003250831A1 (en) 2003-12-31

Family

ID=29724387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250831A Abandoned AU2003250831A1 (en) 2002-06-12 2003-06-12 Use of hec1 antagonists in the treatment of proliferative disorders and cancer

Country Status (3)

Country Link
EP (1) EP1519736A2 (fr)
AU (1) AU2003250831A1 (fr)
WO (1) WO2003105891A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101234281B1 (ko) 2004-04-09 2013-02-18 가부시키가이샤 진케어켄큐쇼 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2007075206A2 (fr) * 2005-09-30 2007-07-05 The Regents Of The University Of California La satb1, un determinant de morphogenese et de metastate tumorale
BRPI0815578B8 (pt) 2007-08-20 2023-01-03 Oncotherapy Science Inc Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
JP5825535B2 (ja) 2010-03-17 2015-12-02 タイヴェックス・セラピューティクス・コーポレイションＴａｉｖｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｈｅｃ１活性の調節因子およびそのための方法
US9976183B2 (en) * 2011-11-21 2018-05-22 Taivex Therapeutics Corporation Biomarkers for cancers responsive to modulators of HEC1 activity
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
TWI640519B (zh) 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6795898A (en) * 1997-04-04 1998-10-30 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis

Also Published As

Publication number Publication date
WO2003105891A3 (fr) 2004-05-06
EP1519736A2 (fr) 2005-04-06
AU2003250831A8 (en) 2003-12-31
WO2003105891A2 (fr) 2003-12-24

Similar Documents

Publication Publication Date Title
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HK1089155A1 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
AU2003223380A1 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
HK1079203A1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
PL369822A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
AU2003250831A1 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
GB0212405D0 (en) Composition and its therapeutic use
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
EP1539100A4 (fr) Compositions et methodes pour le traitement de troubles cutanes
AU2003271016A1 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2002328173A1 (en) Omoxin agonists and antagonists for use in the treatment of metabolic disorders
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2003247094A1 (en) Enhancing the effect of radioimmunotherapy in the treatment of tumors
AU2002363367A1 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
AU2003246880A1 (en) Alkaloid-derived compounds and use thereof in cancer and malaria treatment
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
AU2002328172A1 (en) Agonists and antagonists of modumet for use in the treatment of metabolic disorders
AU2002321774A1 (en) Agonists and antagonists of contabix for use in the treatment of metabolic disorders
AU2002339688A1 (en) Glucoset agonists and antagonists for use in the treatment of metabolic disorders
AU2002339679A1 (en) Glucomin agonists and antagonists for use in the treatment of metabolic disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase